Friday, February 15, 2013

Journal questions use of cannabis spray drug for MS | Synopsis

Journal questions use of cannabis spray drug for MS

Trade Union mural, Islington
Trade Union mural, Islington by Fin Fahey
License (according to Flickr): Attribution-ShareAlike License
Excerpt:

There is little proof to back the use of a cannabis extract spray made by GW Pharmaceuticals for spasticity in clients with multiple sclerosis, according to a medical journal review published on Thursday. GW Pharma said the report in the Drug and Therapeutics Bulletin (DTB), a British Medical Journal publication, provided "a misleading view of the drug" and contained a lot of errors. Sativex is sold as a prescribed drug in Britain by GW's partner, German group Bayer. The under-the-tongue spray was approved by British regulators in 2010 in a major boost for GW, which spent even more than a many years establishing the product. The DTB, nevertheless, said the proof supporting its use was insufficient to validate regimen use. "We believe that such limitations make it difficult to identify the place of this product in clinical practice," the evaluation concluded.

People:

Sativex

Overall Sentiment: 0.038508

Relevance: 0.499436

Additional Info:

Company: GW Pharma

Overall Sentiment: -0.221861

Relevance: 0.872819

Company: GW

Overall Sentiment: 0.334643

Relevance: 0.709434

Company: GW Pharmaceuticals

Overall Sentiment: -0.320509

Relevance: 0.583719

Organization: DTB

Overall Sentiment: -0.10563

Relevance: 0.548071

HealthCondition: multiple sclerosis

Overall Sentiment: -0.111304

Relevance: 0.350961

Disambiguation: DiseaseOrMedicalCondition | CauseOfDeath | DiseaseCause | RiskFactor | Disease | OrganizationSectorReferences:

Drug: cannabis

Overall Sentiment: -0.33223

Relevance: 0.323785

PrintMedia: British Medical Journal

Overall Sentiment: -0.557289

Relevance: 0.438143

Header Info
Posted by at
Labels: , , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)